Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical President CEO Gerald Commissiong will present at the Proactive One2One Virtual Forum on March 17, 2022 at 2:00 PM ET.
Event: Proactive One2One Virtual Forum
Date: March 17, 2022
Time: 2:00 PM ET – 2:30 PM ET
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of cancer, Alzheimer’s disease and COVID-19. Todos’ U.S.-based CLIA/CAP certified diagnostics laboratory Provista Diagnostics, Inc. in Alpharetta, Georgia-based currently performs COVID-19 PCR and neutralizing antibody testing and is expanding its test menu in preparation for the launch of the Company’s proprietary commercial-stage Videssa® breast cancer blood test. Additionally, through its subsidiary Corona Diagnostics, Inc. the Company supplies client CLIA/CAP certified laboratory in the United States with PCR and other diagnostics testing reagents and supplies.
Todos has entered into a joint venture with NLC Pharma, called 3CL Pharma Ltd. that is pursuing the development and commercialization of oral 3CL protease inhibitor supplements products and therapeutics drug candidates for the treatment of nidovirus coronaviruses, including COVID-19, as well as diagnostic tests detecting the 3CL protease inhibitors that target fundamental reproductive and immune evasion mechanisms of coronaviruses. Tollovid® and Tollovid Daily™ are dietary supplement products with authorized 3CL protease inhibitor claims. Tollovir® is an oral antiviral drug candidate that has successfully completed a Phase 2a clinical trial and is being prepared for Emergency Use Authorization submissions in certain jurisdictions as well as a Phase 2b/3 clinical trial.
For more information, please visit https://www.todosmedical.com/